← Back to Search
Coinhibitory Pathways In Immunotherapy For Cancer.
S. Baumeister, G. Freeman, G. Dranoff, A. Sharpe
Published 2016 · Biology, Medicine
Download PDFAnalyze on Scholarcy
The immune system is capable of recognizing tumors and eliminates many early malignant cells. However, tumors evolve to evade immune attack, and the tumor microenvironment is immunosuppressive. Immune responses are regulated by a number of immunological checkpoints that promote protective immunity and maintain tolerance. T cell coinhibitory pathways restrict the strength and duration of immune responses, thereby limiting immune-mediated tissue damage, controlling resolution of inflammation, and maintaining tolerance to prevent autoimmunity. Tumors exploit these coinhibitory pathways to evade immune eradication. Blockade of the PD-1 and CTLA-4 checkpoints is proving to be an effective and durable cancer immunotherapy in a subset of patients with a variety of tumor types, and additional combinations are further improving response rates. In this review we discuss the immunoregulatory functions of coinhibitory pathways and their translation to effective immunotherapies for cancer.
This paper references
Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens
M. M. Gubin (2014)
CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
Y. Zhu (2014)
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
G. Freeman (2000)
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
J. Galon (2006)
Indoleamine 2,3 dioxygenase and metabolic control of immune responses.
D. Munn (2013)
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
S. Woo (2014)
Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II1
B. Liang (2008)
Galectin-9 controls the therapeutic activity of 4-1BB–targeting antibodies
S. Madireddi (2014)
The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood
Peter T Sage (2013)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco (2009)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
J. Taube (2014)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
J. Larkin (2015)
IL-18 induces PD-1-dependent immunosuppression in cancer.
M. Terme (2011)
Immune checkpoint blockade: a common denominator approach to cancer therapy.
S. Topalian (2015)
NFATc1 Regulates PD-1 Expression upon T Cell Activation1
Kenneth J. Oestreich (2008)
Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
M. Nishino (2013)
Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
J. Yang (2007)
Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines
N. Hacohen (2013)
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells
B. Molon (2011)
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
N. Rizvi (2015)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi (2010)
Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity
Z. Guo (2014)
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
E. Lipson (2012)
Vstm3 is a member of the CD28 family and an important modulator of T‐cell function
S. D. Levin (2011)
Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-31
C. Workman (2002)
The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention.
P. Ott (2013)
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
Tryptophan catabolism generates autoimmune-preventive regulatory T cells.
F. Fallarino (2006)
Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma
L. Aguilar (2015)
Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy
D. Johnson (2013)
Spontaneous regression of metastases from melanoma: review of the literature
L. V. Kalialis (2009)
Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
J. Taube (2015)
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.
Joseph F. Grosso (2007)
Phase I/II trial of tremelimumab in patients with metastatic melanoma.
L. Camacho (2009)
Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models
D. Flies (2011)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
A. Snyder (2014)
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
G. Kenter (2009)
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
N. Patsoukis (2015)
Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
Hyun-Tak Jin (2010)
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
Tumor antigens recognized by T lymphocytes.
T. Boon (1994)
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
D. Knight (2013)
An immune-active tumor microenvironment favors clinical response to ipilimumab
R. Ji (2011)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
D. Le (2015)
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.
Scott D Brown (2014)
Protein Kinase C-η Controls CTLA-4-Mediated Regulatory T Cell Function
Kok-Fai Kong (2014)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
J. Brahmer (2015)
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E. Tivol (1995)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
J. Naidoo (2015)
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L. Monney (2002)
Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
J. Matsuzaki (2010)
Notch signaling regulates PD‐1 expression during CD8+ T‐cell activation
M. Mathieu (2013)
Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53
K. W. Yoon (2015)
Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma
M. Smyth (2000)
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
R. Vonderheide (2010)
A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
G. Beatty (2013)
D. Chen (2013)
Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
V. Balachandran (2011)
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
Rikke B. Holmgaard (2013)
CTLA-4 Control over Foxp3+ Regulatory T Cell Function
K. Wing (2008)
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
S. Ansell (2015)
Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell–cell adhesion and signaling mechanism that requires cis-trans receptor clustering
K. F. Stengel (2012)
B70 antigen is a second ligand for CTLA-4 and CD28
M. Azuma (1993)
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4
H. S. Kuehn (2014)
The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling.
O. Met (2006)
Nivolumab in previously untreated melanoma without BRAF mutation.
C. Robert (2015)
Deciphering and reversing tumor immune suppression.
GregÂ T. Motz (2013)
Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing
S. Gameiro (2014)
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.
E. Chiocca (2011)
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
L. Deng (2014)
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
G. Prendergast (2014)
Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses.
Nicole Joller (2014)
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
J. Fu (2015)
Immunologic correlates of the abscopal effect in a patient with melanoma.
M. Postow (2012)
Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours
MichaelJ. Millward (2013)
The phosphatidylserine receptors, T cell immunoglobulin mucin proteins 3 and 4, are markers of histiocytic sarcoma and other histiocytic and dendritic cell neoplasms.
D. Dorfman (2010)
Emerging Tim-3 functions in antimicrobial and tumor immunity.
Kaori Sakuishi (2011)
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
Yanping Xiao (2014)
T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment
S. J. Santegoets (2012)
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
L. Wang (2011)
Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues.
T. Honda (2014)
Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes.
H. Nishimura (1996)
Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9.
M. Gleason (2012)
T-regulatory cells: key players in tumor immune escape and angiogenesis.
A. Facciabene (2012)
Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
Z. Guo (2013)
A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression.
Y. Kikushige (2015)
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
S. Kreiter (2015)
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
A. van Elsas (1999)
Tumor-Infiltrating Lymphocytes in Glioblastoma Are Associated with Specific Genomic Alterations and Related to Transcriptional Class
W. C. Rutledge (2013)
The future of immune checkpoint therapy
P. Sharma (2015)
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
S. Blackburn (2009)
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
Shintaro Iwama (2014)
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens
E. Baixeras (1992)
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
H. Dong (1999)
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC
K. S. Boles (2009)
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
R. Vonderheide (2013)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
E. Kwon (2014)
Cancer immunoediting: from immunosurveillance to tumor escape
Gavin P Dunn (2002)
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
M. Green (2010)
Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)
M. Sznol (2008)
Oncology meets immunology: the cancer-immunity cycle.
D. Chen (2013)
OX40 is a potent immune-stimulating target in late-stage cancer patients.
B. Curti (2013)
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.
L. Deng (2014)
OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.
Robert H. I. Andtbacka (2013)
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.
K. Chung (2010)
Association of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer
Christine G. Joseph (2014)
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
Hepatotoxicity with combination of vemurafenib and ipilimumab.
A. Ribas (2013)
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
C. Zhu (2005)
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance.
Jang-June Park (2010)
Nivolumab plus ipilimumab in advanced melanoma.
J. Wolchok (2013)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
R. Motzer (2015)
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
O. Hamid (2013)
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Michael A. Postow (2015)
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.
S. Demaria (2005)
Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.
A. Tarhini (2012)
Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients—Report of a Phase I/IIa Clinical Trial
A. Legat (2015)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
T. Powles (2014)
A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer.
N. Segal (2014)
Programmed Death-1 (PD-1):PD-Ligand 1 Interactions Inhibit TCR-Mediated Positive Selection of Thymocytes1
M. Keir (2005)
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Seng-Ryong Woo (2012)
CTLA-4–Ig regulates tryptophan catabolism in vivo
U. Grohmann (2002)
The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.
Robert J. Johnston (2014)
Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
P. Sabbatini (2012)
CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.
A. Hurwitz (1998)
PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
Z. Guo (2014)
Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway.
Magdalena J. Polanczyk (2006)
Lymphocyte Activation Gene-3 (CD223) Regulates the Size of the Expanding T Cell Population Following Antigen Activation In Vivo1
C. Workman (2004)
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
E. Akbay (2013)
TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Joe-Marc Chauvin (2015)
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
D. Le (2013)
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chih-Hao Chang (2015)
Restoring function in exhausted CD8 T cells during chronic viral infection
D. Barber (2006)
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
A. V. D. van den Eertwegh (2012)
Integrative genomic analysis of HIV-specific CD8+ T cells reveals that PD-1 inhibits T cell function by upregulating BATF
M. Quigley (2010)
Tissue expression of PD-L1 mediates peripheral T cell tolerance
M. Keir (2006)
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
B. Sangro (2013)
Oncolytic virotherapy for gliomas: steps toward the future.
Johanna K. Kaufmann (2013)
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Yvette Latchman (2001)
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
F. S. Hodi (2014)
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
H. Ueda (2003)
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.
L. Zitvogel (2013)
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
A. Amin (2014)
Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer
D. McNeel (2011)
Enhancing SIV-Specific Immunity In Vivo by PD-1 Blockade
V. Velu (2009)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
P. Tumeh (2014)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
D. Schadendorf (2015)
PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis
B. Zinselmeyer (2013)
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.
P. Ascierto (2010)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
M. Rooney (2015)
Neoantigens in cancer immunotherapy
T. Schumacher (2015)
Balancing natural killer cell activation through paired receptors
L. Martinet (2015)
Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression
R. Bellucci (2015)
SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1
J. Chemnitz (2004)
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
F. S. Hodi (2014)
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
P. Waterhouse (1995)
OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma.
H. Kaufman (2010)
Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand
B. Huard (2004)
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.
S. Slovin (2013)
B7-H1 limits the entry of effector CD8+ T cells to the memory pool by upregulating Bim
Rachel M. Gibbons (2012)
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
R. Parry (2005)
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L Maude (2014)
CTLA-4 blockade in tumor models: an overview of preclinical and translational research.
Joseph F. Grosso (2013)
Combining immunotherapy and targeted therapies in cancer treatment
M. Vanneman (2012)
Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy
B. Lo (2015)
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
T. Lynch (2012)
An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer
E. Golden (2013)
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
X. Yu (2009)
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
E. Romano (2015)
Regulation of surface and intracellular expression of CTLA4 on mouse T cells.
M. Alegre (1996)
Autosomal-dominant immune dysregulation syndrome in humans with CTLA4 mutations
Désirée Schubert (2014)
Cutting Edge: Accelerated Autoimmune Diabetes in the Absence of LAG-3
M. Bettini (2011)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
A. Ribas (2015)
Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
Y. Ishida (1992)
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
T. Okazaki (2013)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
D. Zamarin (2014)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
M. Butte (2007)
Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor
M. Callahan (2013)
CTLA-4 Blockade Enhances Antitumor Immunity of Intratumoral Injection of Immature Dendritic Cells into Irradiated Tumor in a Mouse Colon Cancer Model
Cheol-Hun Son (2014)
Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment
A. Zippelius (2015)
Activity of Anti-PD-1 in Murine Tumor Models: Role of “Host” PD-L1 and Synergistic Effect of Anti-PD-1 and Anti-CTLA-4 (48.37)
A. Korman (2007)
Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family
Jennifer J. McIntire (2001)
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
H. Soliman (2014)
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
R. Schreiber (2011)
Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma.
Geoffrey T. Gibney (2014)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
J. Taube (2012)
T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells
R. Dekruyff (2010)
TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
Y. Kikushige (2010)
Vemurafenib sensitivity skin reaction after ipilimumab.
J. Harding (2012)
Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
O. Qureshi (2011)
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.
Kristin M. Sanderson (2005)
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
T. Okazaki (2011)
CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.
Y. Naito (1998)
Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
B. Rini (2011)
Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.
I. Puzanov (2014)
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
P. Robbins (2014)
IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity
S. Terawaki (2011)
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
C. Robert (2015)
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
J. Liu (2015)
Role of LAG-3 in regulatory T cells.
C. Huang (2004)
VISTA Regulates the Development of Protective Antitumor Immunity.
I. Le Mercier (2014)
Intrinsic and extrinsic control of peripheral T‐cell tolerance by costimulatory molecules of the CD28/ B7 family
Hélène Bour-Jordan (2011)
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Yu-Hwa Huang (2015)
Differentiation of Embryonic Stem Cells 1 (Dies1) Is a Component of Bone Morphogenetic Protein 4 (BMP4) Signaling Pathway Required for Proper Differentiation of Mouse Embryonic Stem Cells*
Luigi Aloia (2009)
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
R. Vonderheide (2007)
Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
Nicole Joller (2011)
T-bet represses expression of PD-1 and sustains virus-specific CD8 T cell responses during chronic infection
Charlly Kao (2011)
Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo
Nicholas M. Durham (2014)
The interaction properties of costimulatory molecules revisited.
A. V. Collins (2002)
Effects of Vascular Endothelial Growth Factor on the Lymphocyte-Endothelium Interactions: Identification of Caveolin-1 and Nitric Oxide as Control Points of Endothelial Cell Anergy1
C. Bouzin (2007)
Patient Responses to Ipilimumab, a Novel Immunopotentiator for Metastatic Melanoma: How Different are these From Conventional Treatment Responses?
G. Pennock (2012)
Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells
M. Smyth (2000)
A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects.
S. Strome (2007)
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors
S. de Vos (2014)
Myeloid-derived suppressor cells as regulators of the immune system
D. Gabrilovich (2009)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark Selby (2013)
Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
M. Ogura (2014)
Can skin cancers be minimized or prevented in organ transplant patients?
J. McCann (1999)
VISTA is an immune checkpoint molecule for human T cells.
J. L. Lines (2014)
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
J. Brahmer (2010)
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.
Leticia Corrales (2015)
PD-1 and its ligands in tolerance and immunity.
M. Keir (2008)
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
A. Ribas (2013)
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer
E. Small (2007)
LAG-3 in Cancer Immunotherapy.
Monica V. Goldberg (2011)
Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma
J. Luke (2015)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
J. Wolchok (2009)
Tumors: Wounds That Do Not Heal—Redux
H. Dvorak (2015)
The STING pathway and the T cell-inflamed tumor microenvironment.
S. Woo (2015)
Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity
L. Wang (2014)
TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity
G. Freeman (2010)
Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin
H. Wei (2013)
Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses
R. P. Sutmuller (2001)
Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4
T. Takahashi (2000)
Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.
G. Freeman (1993)
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.
M. Reck (2013)
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
A. Ribas (2005)
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
V. Shankaran (2001)
Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
R. Berger (2008)
Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
M. Curran (2011)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
M. Curran (2010)
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
F. S. Hodi (2008)
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
B. Fife (2009)
This paper is referenced by
PD-1/PD-L1 antagonists in gastric cancer: Current studies and perspectives
Jian Li (2019)
The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy
A. R. Lim (2020)
Emerging roles of p53 and other tumour-suppressor genes in immune regulation
C. Muñoz-Fontela (2016)
Monalizumab: inhibiting the novel immune checkpoint NKG2A
T. van Hall (2019)
Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy.
I. Vitale (2019)
Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade
Mohammad Rashidian (2019)
Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation
G. Mondanelli (2020)
The prognostic impact of immune-related markers in non-small cell lung cancer
S. Hald (2017)
Targeting CXCR4-dependent immunosuppressive Ly6Clow monocytes improves antiangiogenic therapy in colorectal cancer
K. Jung (2017)
Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer
Shuang Zhang (2018)
TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.
H. Liu (2018)
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
L. Gauthier (2019)
Checkpoint inhibitors for the treatment of JC virus-related progressive multifocal leukoencephalopathy.
E. Beck (2020)
Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy.
G. Shi (2019)
Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts
C. Goletz (2018)
Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities.
Kole T. Roybal (2017)
Immunotherapy: a new era for hepatocellular carcinoma
Ya-jing He (2018)
The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy
L. Long (2018)
PD‐1 is highly expressed by neoplastic B‐cells in Richter transformation
A. Behdad (2019)
Immune checkpoint blockade in infectious diseases
M. Wykes (2018)
Interferon β and Anti-PD-1/PD-L1 Checkpoint Blockade Cooperate in NK Cell-Mediated Killing of Nasopharyngeal Carcinoma Cells
A. Makowska (2019)
Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity.
Daniel Álvarez-Sierra (2019)
Coalescing Lessons from Oxygen Sensing, Tumor Metabolism, and Epigenetics to Target VHL loss in Kidney Cancer.
A. Chakraborty (2020)
The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers.
Geng Wang (2020)
Programmed cell death‐1 (PD‐1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell–intrinsic PD‐1
H. Li (2017)
Fatty Acid Oxidation Controls CD8+ Tissue-Resident Memory T-cell Survival in Gastric Adenocarcinoma
R. Lin (2020)
Immune microenvironment in different molecular subtypes of ductal breast carcinoma
Mona Sadeghalvad (2020)
Gene-modified dendritic cell vaccines for cancer.
R. Abraham (2016)
PD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond
Y. Ishida (2020)
Phagocytosis checkpoints as new targets for cancer immunotherapy
Mingye Feng (2019)
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.
Shetal A Patel (2018)
Myosin II Synergizes with F-Actin to Promote DNGR-1-Dependent Cross-Presentation of Dead Cell-Associated Antigens
O. Schulz (2018)See more